Hypothyroidism News and Research RSS Feed - Hypothyroidism News and Research

Hypothyroidism occurs when the thyroid gland does not produce enough thyroid hormone to meet the body’s needs. Without enough thyroid hormone, many of the body’s functions slow down. About 5 percent of the U.S. population has hypothyroidism. Women are much more likely than men to develop hypothyroidism.
Endocrine Society issues new guidelines on hypopituitarism

Endocrine Society issues new guidelines on hypopituitarism

The Endocrine Society today issued a Clinical Practice Guideline that recommends treating insufficient hormone levels in individuals with hypopituitarism by replacing hormones at levels as close to the body's natural patterns as possible. [More]
Patients with hypothyroidism have nagging symptoms despite normal TSH tests, medication use

Patients with hypothyroidism have nagging symptoms despite normal TSH tests, medication use

About 15 percent of the 10-12 million people in the U.S. with hypothyroidism, or an underactive thyroid, continue to feel sick despite following the standard of care recommended by the American Thyroid Association. [More]
Japanese researchers discover causative gene for common type of hearing loss

Japanese researchers discover causative gene for common type of hearing loss

A causative gene for a highly common type of hearing loss (sensorineural hearing loss, or SNHL) has been identified by a group of Japanese researchers, who successfully replicated the condition using a transgenic mouse. [More]
Headache disorders may increase risk of thyroid condition

Headache disorders may increase risk of thyroid condition

Sufferers of migraines, cluster headaches, tension headaches or other headache disorders are at greater risk of developing a thyroid condition called hypothyroidism, according to a study by University of Cincinnati College of Medicine researchers. [More]
CIRM approves $5.2 million for research on life-long treatment for rare childhood disease

CIRM approves $5.2 million for research on life-long treatment for rare childhood disease

Cystinosis is a rare disease that usually strikes children before they are two years old and can lead to end stage kidney failure before their tenth birthday. [More]
PolyU researchers discover inadequate intakes of micronutrients among Hong Kong lactating women

PolyU researchers discover inadequate intakes of micronutrients among Hong Kong lactating women

While breastfeeding has become more common across the globe in recent years, lactating women may not be aware of the nutrient adequacy of their breast milk and how their daily diet affects their nutrition intakes. [More]
Moderately high TSH concentrations in infants linked to neurodevelopmental outcomes at school age

Moderately high TSH concentrations in infants linked to neurodevelopmental outcomes at school age

Babies born with moderately high concentrations of thyroid stimulating hormone have a higher risk of poor educational and development outcomes at school age, a world-first University of Sydney study reveals. [More]
Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Mallinckrodt plc, a leading global specialty biopharmaceutical company, today announced new retrospective health economic data on H.P. Acthar® Gel (repository corticotropin injection; RCI), which may be an option for the management of multiple sclerosis (MS) relapses. [More]
Maternal hypothyroxinemia may contribute to increased risk of schizophrenia in infants

Maternal hypothyroxinemia may contribute to increased risk of schizophrenia in infants

A study published in Biological Psychiatry reveals a new link between low levels of the thyroid hormone thyroxine during pregnancy and risk of schizophrenia in the offspring. [More]
Latest and final review of health problems related to Agent Orange exposure during Vietnam War

Latest and final review of health problems related to Agent Orange exposure during Vietnam War

The latest and final in a series of congressionally mandated biennial reviews of the evidence of health problems that may be linked to exposure to Agent Orange and other herbicides used during the Vietnam War changed the categorization of health outcomes for bladder cancer, hypothyroidism, and spina bifida and clarified the breadth of the previous finding for Parkinson's disease. [More]
Reclaim Your Sleep survey: 46% of female patients waiting over five years to be diagnosed with sleep apnoea

Reclaim Your Sleep survey: 46% of female patients waiting over five years to be diagnosed with sleep apnoea

46% of female patients with sleep apnoea are suffering with sleep problems for over five years before being correctly diagnosed with the condition. [More]
Novel strategies on the way for difficult-to-treat head and neck cancer

Novel strategies on the way for difficult-to-treat head and neck cancer

Novel strategies are on the way for difficult-to-treat and advanced head and neck cancer, the most heterogeneous group of malignancies which are generally associated with poor survival, and encouraging results have been presented at the first ESMO Asia 2015 Congress in Singapore. [More]
Lilly, Merck announce another immuno-oncology collaboration

Lilly, Merck announce another immuno-oncology collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types. [More]
Lilly, Merck expand oncology clinical trial collaboration

Lilly, Merck expand oncology clinical trial collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC). [More]
Discovery may lead to development of cell-based regenerative therapy to restore thyroid function

Discovery may lead to development of cell-based regenerative therapy to restore thyroid function

A discovery made by investigators from Beth Israel Deaconess Medical Center and the Boston University School of Medicine may help lead to the development of a cell-based regenerative therapy which could be used to restore thyroid function in patients with cancer who have had their thyroids surgically removed and children born with congenital hypothyroidism. [More]
First-line TKI adverse event profile has no bearing on second-line RCC treatment choice

First-line TKI adverse event profile has no bearing on second-line RCC treatment choice

In metastatic renal cell carcinoma patients, there is no significant correlation between adverse event profiles of first- and second-line tyrosine kinase inhibitors, suggests a Japanese study. [More]
New computational model may help overcome misalignment of U.S. biomedical research resources

New computational model may help overcome misalignment of U.S. biomedical research resources

A new computational model developed by scientists from the University of Chicago could help improve the allocation of U.S. biomedical research resources. [More]
World expert panel recommends routine brain health screening for adults older than 70

World expert panel recommends routine brain health screening for adults older than 70

A panel of world experts in aging convened at Saint Louis University recommended that everyone 70 and older should have their memory and reasoning ability evaluated annually by a doctor or health care provider. [More]
Vernalis Therapeutics announces availability of codeine-based cough and cold syrup in the U.S.

Vernalis Therapeutics announces availability of codeine-based cough and cold syrup in the U.S.

Vernalis Therapeutics Inc., a subsidiary of Vernalis plc, today announced that Tuzistra XR (codeine polistirex and chlorpheniramine polistirex), extended-release oral suspension, CIII (DEA Schedule III) is now available to adult patients and physicians in the United States. [More]
Amgen to present data on Repatha (evolocumab) and observational studies at ESC Congress 2015

Amgen to present data on Repatha (evolocumab) and observational studies at ESC Congress 2015

Amgen today announced that it will present six abstracts at the upcoming ESC Congress 2015, organized by the European Society of Cardiology, being held Aug. 29 – Sept. 2 in London. [More]
Advertisement